Dystrogen Therapeutics

Dystrogen Therapeutics is a clinical-stage chimeric cell therapy company focusing on rare diseases. The company is currently testing in humans the Dystrophic Expressing Chimeric (DEC) cell therapy for Duchenne Muscular Dystrophy – a terminal illness that affects young boys and lead the gradually worsening dysfunction of the muscular system.